PedersenN. C.,
HoE. W.,
BrownM. L.,
YamamotoJ. K. Isolation of T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science1987; 235:790–793
HopperC. D.,
SparkesA. H.,
HarbourD. A. Feline immune-deficiency virus. In
ChandlerE. A.,
GaskellC. J.,
GaskellR. M.
(eds) Feline medicine and therapeutics 2nd edn Oxford: Blackwell Scientific Publications; 1994488
BrownE. W.,
MiththapalaS.,
O’BrienS. J. Prevalence of exposure to feline immunodeficiency virus in exotic felid species. J Zool Wildl Med1993; 24:357–364
SodoraD. L.,
ShpaerE. G.,
KitchellB. E.,
DowS. W.,
HooverE. A.,
MullinsJ. I. Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns. J Virol1994; 68:2230–2238
PhillipsT. R.,
LamontC.,
KoningsD. A Identification of the Rev transactivation and Rev-responsive elements of feline immunodeficiency virus. J Virol1992; 66:5464–5471
RigbyM. A.,
HolmesE. C.,
PistelloM.,
MackayA.,
Leigh BrownA. J.,
NeilJ. C. Evolution of structural proteins of feline immunodeficiency virus: molecular epidemiology and evidence of selection for change. J Gen Virol1993; 74:425–436
SiebelinkK. H. J.,
RimmelzwaanG. F.,
BoschM. L.,
MeloenR. H.,
OsterhausA. D. M. E. A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. J Virol1993; 67:2202–2208
LombardiS.,
GarzelliC.,
La RosaC. Identification of a linear neutralization site within the 3rd variable region of the feline immunodeficiency virus envelope. J Virol1993; 67:4742–4749
SellonR. K.,
JordanH. L.,
Kennedy-StoskopfS.,
TompkinsM. B.,
TompkinsW. H. Feline immunodeficiency virus can be experimentally transmitted via milk during acute maternal infection. J Virol1994; 68:3380–3385
BishopS. A.,
WhitingC. V.,
Gruffydd-JonesT. J.,
HarbourD. A.,
StokesC. R. Aspects of mucosal immunopathogenesis with FIV. Abstract in Medical Research Council 7th Annual AIDS Workshop; Brighton: 1993
GeorgeJ. W.,
PedersenN. C.,
HigginsJ. The effect of age on the course of experimental feline immunodeficiency virus infection in cats. AIDS Res Hum Retroviruses1993; 9:897–905
WillettB. J.,
HosieM. J.,
JarrettO.,
NeilJ. C. Identification of a putative cellular receptor for feline immunodeficiency virus as the feline homolog of CD9. Immunology1994; 81:228–233
WillettB. J.,
HosieM. J.,
CallananJ. J.,
NeilJ. C.,
JarrettO. Infection with feline immunodeficiency virus is followed by the rapid expansion of a CD8+ lymphocyte subset. Immunology1993; 78:1–6
PantaleoG.,
DemarestJ. F.,
SoudeynsH. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV. Nature1994; 370:463–467
SheltonG. H.,
GrantC. K.,
CotterS. M.,
GardnerM. B.,
HardyW. D.,
DiaGiacomoR. F. Feline immunodeficiency virus and feline leukemia virus infections and their relationships to lymphoid malignancies in cats: a retrospective study (1968–88). J Acquir Immune Defic Syndr1990; 3:623–630
ThomasJ. B.,
RobinsonW. F.,
ChadwickB. J.,
RobertsonI. D.,
BeetsonS. A. Association of renal-disease indicators with feline immunodeficiency virus infection. J Am Anim Hosp Assoc1993; 29:320–326
EnglishR. V.,
DavidsonM. G.,
NaisseM. P.,
JamiesonV. E.,
LapinM. R. Intraocular disease associated with feline immunodeficiency virus infection in cats. J Am Vet Med Assoc1990; 196:1116–1119
NorthT. W.,
NorthG. L. T.,
PedersenN. C. Feline immune-deficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother1989; 33:915–919
EgberinkH.,
BorstM.,
NiphuisH. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phospho-nomethoxyethyl) adenine. Proc Natl Acad Sci USA1990; 87:3087–3091
CronnR. C.,
RemingtonK. M.,
PrestonB. D.,
NorthT. W. Inhibition of reverse transcriptase from feline immunodeficiency virus by analogs of 2′deoxyadenosine-5′-triphosphate. Biochem Pharmacol1992; 44:1375–1381
SmythN. R.,
McCrackenC. M.,
GaskellR. M Susceptibility in cell culture of feline immunodeficiency virus to eighteen compounds. J Antimicrob Chemother1994; 34:589–594
Tanabe-TochikuraA.,
TochikuraT. S.,
BlakesleeJ. R.,
OlsenR. G.,
MathesL. E. Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FlV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro. Antiviral Res1992; 19:161–172
HartmannK.,
DonathA.,
BeerB. Use of two virustatica (AZT, PMEA) in the treatment of FIV and FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol1992; 35:167–175
HayesK. A.,
LafradoL. J.,
EricksonJ. G.,
MarrJ. M.,
MathesL. E. Prophylactic ZDV therapy prevents early viraemia and lymphocyte decline but not primary infection in feline immunodeficiency virus inoculated cats. J Acquir Immune Defic Syndr1993; 6:127–134
MeersJ.,
del FierroG. M.,
CopeR. B.,
ParkH. S.,
GreeneW. K.,
RobinsonW. F. Feline immunodeficiency virus infection: plasma but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine. Arch Virol1993; 132:67–81
SmythN. R.,
BennettM.,
GaskellR. M.,
McCrackenC. M.,
HartC. A.,
HoweJ. L. Effect of 3′azido–2′, 3′–deoxythymidine on experimental feline immunodeficiency virus infection of domestic cats. Res Vet Sci1994; 57:220–224